Innovstone Therapeutics divulges new LRRK2 inhibitors for Parkinson’s disease
April 4, 2025
Innovstone Therapeutics Ltd. has synthesized leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.